RxSight Secures $60M Upfront, Up to $140M Milestones in Alcon PCIOL Development Deal
RXST is trading near its 52-week low of $4.48 (13% above the low).
Summary
RxSight will receive a $60 million upfront payment and up to $140 million in additional milestone payments from Alcon as part of a new collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership is highly significant for RxSight, providing substantial funding and leveraging Alcon's global commercialization strength for its light-adjustable technology. For Alcon, the deal enhances its leading PCIOL portfolio with innovative tunable lens technology, aiming to improve post-cataract surgery outcomes. RxSight will handle development and manufacturing, while Alcon leads global sales, with RxSight also earning royalties on net sales.
At the time of this announcement, RXST was trading at $5.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231.8M. The 52-week trading range was $4.48 to $13.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.